2:14 PM
Nov 10, 2017
 |  BC Extra  |  Company News

Management tracks: Immunomedics, WuXi

Antibody company Immunomedics Inc. (NASDAQ:IMMU) appointed Michael Pehl president and CEO, effective Dec. 7, and Brendan Delaney chief commercial officer. Interim CEO Michael Garone will resume his role as CFO. Pehl was president of hematology & oncology, and Delaney was VP of U.S. commercial hematology oncology, both at Celgene Corp. (NASDAQ:CELG).

Contract genomics services...

Read the full 250 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >